IP Library › Granted Patent US 12,428,418
Granted Patent B2
US 12,428,418 · App. 18/745,768 · Granted Sep 30, 2025

Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Inventors: John Kincaid (Boston, MA); Matthew Duncton (Boston, MA)
Assignee: NFLECTION THERAPEUTICS, INC.
C07D471/04A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,418
App. No.
18/745,768
Granted
Sep 30, 2025
Kind
B2
Abstract

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X 1 , R 1 , R 2 , R 2a , R 3 , R 3a , and R 3b are as described herein.

Claims (7)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having the structure:

3. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound having the structure:

and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2025
From: KINCAID, JOHN; DUNCTON, MATTHEW
To: NFLECTION THERAPEUTICS, INC.
Reel/Frame 070825/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2025
From: KINCAID, JOHN; DUNCTON, MATTHEW
To: NFLECTION THERAPEUTICS, INC.
Reel/Frame 070825/0363 →
Continuity (5)
Division 17399661 · Aug 11, 2021
Division 16615086
Provisional Application 62663202 · Apr 26, 2018
Provisional Application 62508997 · May 19, 2017
Related Publication 20250034137A1 · Jan 30, 2025
References Cited (53)
US 11161845B2 · Kincaid · 2021 [cited by examiner]
US 12065439B2 · Kincaid · 2024 [cited by examiner]
US 20130345181A1 · Bavetsias et al. · 2013 [cited by applicant]
CN 105384754A · 2016 [cited by applicant]
WO WO2006130160 · 2006 [cited by applicant]
WO WO2007002433 · 2007 [cited by applicant]
WO WO2007088345 · 2007 [cited by applicant]
WO WO2008020206 · 2008 [cited by applicant]
WO WO2008024724 · 2008 [cited by applicant]
WO WO2008024725 · 2008 [cited by applicant]
WO WO2008055236 · 2008 [cited by applicant]
WO WO2008067481 · 2008 [cited by applicant]
WO WO2008148034 · 2008 [cited by applicant]
WO WO2009082687 · 2009 [cited by applicant]
WO WO2009093008 · 2009 [cited by applicant]
WO WO2009093009 · 2009 [cited by applicant]
WO WO2009093013 · 2009 [cited by applicant]
WO WO2009153554 · 2009 [cited by applicant]
WO WO2012040636 · 2012 [cited by applicant]
WO WO2014179785 · 2014 [cited by applicant]
Adams et al., “Design and Synthesis of Orally Available MEK Inhibitors With Potent in Vivo Antitumor Efficacy,” Bioorganic & Medicinal Chemistry Letters, 22(7), pp. 2411-2414 (2012). [cited by applicant]
Akinleye et al., “MEK and the Inhibitors: From Bench to Bedside,” Journal of Hematology & Oncology, 6(27), 11 pages (2013). [cited by applicant]
Hatzivassiliou et al., “Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers,” Nature, 501(7466), pp. 232-236 (2013). [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2018/033544 mailed Aug. 9, 2018 (11 pages). [cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2018/033547, mailed Aug. 9, 2018 (11 pages). [cited by applicant]
Laing et al., “Fused Thiophene Derivatives as MEK Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 22(1), pp. 472-475 (2012). [cited by applicant]
Wallace et al., “Structure-based Design and Synthesis of Pyrrole Derivatives as MEK Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 20(14), pp. 4156-4158 (2010). [cited by applicant]
RN 1347327-80-3 Registry ED Entered STN: Dec. 2, 2011. [cited by applicant]
RN 1347341-78-9 Registry ED Entered STN: Dec. 2, 2011. [cited by applicant]
RN 1347421-15-1 Registry ED Entered STN: Dec. 2, 2011. [cited by applicant]
RN 1348075-68-2 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348201-64-8 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348347-40-9 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348375-35-8 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348394-69-3 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348492-53-4 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348494-88-1 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348595-42-5 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348618-58-5 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348655-12-8 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1348673-54-0 Registry ED Entered STN: Dec. 4, 2011. [cited by applicant]
RN 1349147-82-5 Registry ED Entered STN: Dec. 5, 2011. [cited by applicant]
RN 1349255-80-6 Registry ED Entered STN: Dec. 5, 2011. [cited by applicant]
RN 1349369-24-9 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349383-92-1 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349420-35-4 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349476-92-1 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349510-77-5 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349524-53-3 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349623-68-2 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349668-73-0 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349887-30-4 Registry ED Entered STN: Dec. 6, 2011. [cited by applicant]
RN 1349985-90-5 Registry ED Entered STN: Dec. 7, 2011. [cited by applicant]